With a strong body of evidence from human peripheral blood and preclinical animal studies spurring the development of FKBP51-targeting drugs for psychiatric disorders, it has long been crucial to close the gap on how FKBP51 is cell type-specifically affected directly in the human brain [43]. This evidence concerns the gene FKBP5 and psychiatric disorder.